Skip to main content
. 2015 Jun;11(6 Suppl 3):1–23.

Figure 5.

Figure 5.

SVR12 in a trial evaluating retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with an additional course of ledipasvir/sofosbuvir. RAV, resistance-associated variants; SVR12, sustained virologic response at week 12. Adapted from Lawitz E et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks [EASL abstract O005]. J Hepatol. 2015;62(1)(suppl).1